CoChat
Sign Up
Cited by 88

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Surface modification strategies in translocating nano-vesicles across different barriers and the role of bio-vesicles in improving anticancer therapy

Tiwari, Pratiksha, Yadav, Krishna, Shukla, Ravi Prakash, Gautam, Shalini, Marwaha, Disha, Sharma, Madhu, Mishra, Prabhat Ranjan·2023·Journal of Controlled Release
DOI 10.1016/j.jconrel.2023.09.016
Open this paper in CoChat — free account

Abstract

Nanovesicles and bio-vesicles (BVs) have emerged as promising tools to achieve targeted cancer therapy due to their ability to overcome many of the key challenges currently being faced with conventional chemotherapy. These challenges include the diverse and often complex pathophysiology involving the progression of cancer, as well as the various biological barriers that circumvent therapeutic molecules reaching their target site in optimum concentration. The scientific evidence suggests that surface-functionalized nanovesicles and BVs camouflaged nano-carriers (NCs) both can bypass the established biological barriers and facilitate fourth-generation targeting for the improved regimen of treatment. In this review, we intend to emphasize the role of surface-functionalized nanovesicles and BVs camouflaged NCs through various approaches that lead to an improved internalization to achieve improved and targeted oncotherapy. We have explored various strategies that have been employed to surface-functionalize and biologically modify these vesicles, including the use of biomolecule functionalized target ligands such as peptides, antibodies, and aptamers, as well as the targeting of specific receptors on cancer cells. Further, the utility of BVs, which are made from the membranes of cells such as mesenchymal stem cells (MSCs), white blood cells (WBCs), red blood cells (RBCs), platelets (PLTs) as well as cancer cells also been investigated. Lastly, we have discussed the translational ch…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2023.09.016

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 420

  1. Schirrmacher, 2019, From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review), Int. J. Oncol., 54, 407, 10.3892/ijo.2018.4661 · DOI
  2. Marwaha, 2023, Synergistic delivery of Imatinib through multifunctional nano-crystalline capsules, in response to redox environment for improved breast cancer therapy, Colloids Surf. B: Biointerfaces, 226, 10.1016/j.colsurfb.2023.113316 · DOI
  3. Bertram, 2000, The molecular biology of cancer, Mol. Asp. Med., 21, 167, 10.1016/S0098-2997(00)00007-8 · DOI
  4. Khadka, 2014, Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability, Asian J. Pharm. Sci., 9, 304
  5. Banala, 2019, Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression, Biomater. Sci., 7, 2889, 10.1039/C9BM00221A · DOI
  6. Shukla, 2021, Development of putrescine anchored nano-crystalsomes bearing doxorubicin and oleanolic acid: deciphering their role in inhibiting metastatic breast cancer, Biomater. Sci., 9, 1779, 10.1039/D0BM01033B · DOI
  7. Gautam, 2023, Self-assembled redox-sensitive polymeric nanostructures facilitate the intracellular delivery of paclitaxel for improved breast cancer therapy, Mol. Pharm., 20, 10.1021/acs.molpharmaceut.2c00673 · DOI
  8. Banala, 2018, Synchronized ratiometric codelivery of metformin and topotecan through engineered nanocarrier facilitates in vivo synergistic precision levels at tumor site, Adv. Healthc. Mater., 7, 10.1002/adhm.201800300 · DOI
  9. Wu, 2022, Extracellular vesicles: emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy, Drug Deliv., 29, 2513, 10.1080/10717544.2022.2104404 · DOI
  10. Bajracharya, 2022, Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems, Drug Deliv., 29, 1959, 10.1080/10717544.2022.2089296 · DOI
  11. Lin, 2019, Exosome-like nanoplatform modified with targeting ligand improves anti-cancer and anti-inflammation effects of imperialine, J. Control. Release Off. J. Control. Release Soc., 311–312, 104, 10.1016/j.jconrel.2019.08.037 · DOI
  12. Urandur, 2020, Theranostic lyotropic liquid crystalline nanostructures for selective breast cancer imaging and therapy, Acta Biomater., 113, 522, 10.1016/j.actbio.2020.06.023 · DOI
  13. Zhang, 2018, Biomacromolecules as carriers in drug delivery and tissue engineering, Acta Pharm. Sin. B, 8, 34, 10.1016/j.apsb.2017.11.005 · DOI
  14. Lee, 2022, Challenges and opportunities of nanotechnology in cancer immunotherapy, Eng. Technol. Clin. Transl., 197
  15. Phan, 2020, The dormant cancer cell life cycle, Nat. Rev. Cancer, 20, 398, 10.1038/s41568-020-0263-0 · DOI
  16. Emami Nejad, 2021, The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment, Cancer Cell Int., 21, 62, 10.1186/s12935-020-01719-5 · DOI · Paper page
  17. Chang, 2016, Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance, Medicine (Baltimore), 95
  18. Valastyan, 2011, Tumor metastasis: molecular insights and evolving paradigms, Cell., 147, 275, 10.1016/j.cell.2011.09.024 · DOI · Paper page
  19. Montemagno, 2020, Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs, Front. Cell Dev. Biol., 8, 10.3389/fcell.2020.00584 · DOI
  20. Dagogo-Jack, 2018, Tumour heterogeneity and resistance to cancer therapies, Nat. Rev. Clin. Oncol., 15, 81, 10.1038/nrclinonc.2017.166 · DOI · Paper page
  21. Sharma, 2022, Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer, J. Control. Release, 346, 43, 10.1016/j.jconrel.2022.04.007 · DOI · Paper page
  22. Shi, 2013, Systemic delivery of microRNA-34a for cancer stem cell therapy, Angew. Chem. Int. Ed., 52, 3901, 10.1002/anie.201208077 · DOI
  23. Gao, 2014, Nanotechnology for the detection and kill of circulating tumor cells, Nanoscale Res. Lett., 9, 500, 10.1186/1556-276X-9-500 · DOI
  24. Polidoro, 2020, Tumor microenvironment in primary liver tumors: a challenging role of natural killer cells, World J. Gastroenterol., 26, 4900, 10.3748/wjg.v26.i33.4900 · DOI
  25. Singh, 2023, Novel biotherapeutics targeting biomolecular and cellular approaches in diabetic wound healing, Biomedicines., 11, 10.3390/biomedicines11020613 · DOI
  26. Ma, 2008, Combination of antiangiogenesis with chemotherapy for more effective cancer treatment, Mol. Cancer Ther., 7, 3670, 10.1158/1535-7163.MCT-08-0715 · DOI
  27. Zheng, 2016, Carbon-dot-decorated carbon nitride nanoparticles for enhanced photodynamic therapy against hypoxic tumor via water splitting, ACS Nano, 10, 8715, 10.1021/acsnano.6b04156 · DOI
  28. Betzer, 2017, In vivo neuroimaging of exosomes using gold nanoparticles, ACS Nano, 11, 10883, 10.1021/acsnano.7b04495 · DOI
  29. De Jong, 2008, Drug delivery and nanoparticles:applications and hazards, Int. J. Nanomedicine, 3, 133, 10.2147/IJN.S596 · DOI
  30. Prokop, 2008, Nanovehicular intracellular delivery systems, J. Pharm. Sci., 97, 3518, 10.1002/jps.21270 · DOI
  31. Kadry, 2020, A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity, Fluids Barriers CNS., 17, 69, 10.1186/s12987-020-00230-3 · DOI · Paper page
  32. Hervé, 2008, CNS delivery via adsorptive transcytosis, AAPS J., 10, 455, 10.1208/s12248-008-9055-2 · DOI · Paper page
  33. Liu, 2017, A dual-mediated liposomal drug delivery system targeting the brain: rational construction, integrity evaluation across the blood-brain barrier, and the transporting mechanism to glioma cells, Int. J. Nanomedicine, 12, 2407, 10.2147/IJN.S131367 · DOI
  34. Belhadj, 2017, Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery, J. Control. Release, 255, 132, 10.1016/j.jconrel.2017.04.006 · DOI
  35. Steeg, 2021, The blood–tumour barrier in cancer biology and therapy, Nat. Rev. Clin. Oncol., 18, 696, 10.1038/s41571-021-00529-6 · DOI
  36. Wang, 2014, Anticancer efficacy and absorption, distribution, metabolism, and toxicity studies of aspergiolide A in early drug development, Drug Des. Devel. Ther., 8, 1965
  37. Shukla, 2020, Multifunctional hybrid nanoconstructs facilitate intracellular localization of doxorubicin and genistein to enhance apoptotic and anti-angiogenic efficacy in breast adenocarcinoma, Biomater. Sci., 8, 1298, 10.1039/C9BM01246J · DOI
  38. Tan, 2021, Improved bioavailability of poorly soluble drugs through gastrointestinal muco-adhesion of lipid nanoparticles, Pharmaceutics., 13, 10.3390/pharmaceutics13111817 · DOI
  39. Moosavian, 2016, Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model, Colloids Surf. B: Biointerfaces, 139, 228, 10.1016/j.colsurfb.2015.12.009 · DOI
  40. Chari, 2008, Targeted cancer therapy: conferring specificity to cytotoxic drugs, Acc. Chem. Res., 41, 98, 10.1021/ar700108g · DOI
  41. Shaker, 2015, Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes, Int. J. Pharm., 493, 285, 10.1016/j.ijpharm.2015.07.041 · DOI
  42. Vestad, 2017, Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study, J. Extracell. Vesicles., 6, 10.1080/20013078.2017.1344087 · DOI
  43. Yadav, 2021, Nanovesicles delivery approach for targeting steroid mediated mechanism of antipsoriatic therapeutics, J. Drug Deliv. Sci. Technol., 65
  44. Omidi, 2014, Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines, Bioimpacts., 4, 55
  45. Miele, 2012, Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy, Int. J. Nanomedicine, 7, 3637
  46. Ozpolat, 2014, Liposomal siRNA nanocarriers for cancer therapy, Adv. Drug Deliv. Rev., 66, 110, 10.1016/j.addr.2013.12.008 · DOI
  47. Demir, 2021, Carbon dots and curcumin-loaded CD44-Targeted liposomes for imaging and tracking cancer chemotherapy: a multi-purpose tool for theranostics, J. Drug Deliv. Sci. Technol, 62
  48. Díaz, 2013, Nanoparticles as drug delivery systems in cancer medicine: emphasis on RNAi-containing nanoliposomes, Pharmaceuticals., 6, 1361, 10.3390/ph6111361 · DOI
  49. Bertrand, 2014, Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology, Adv. Drug Deliv. Rev., 66, 2, 10.1016/j.addr.2013.11.009 · DOI
  50. Jiang, 2017, Red blood cell membrane-camouflaged melanin nanoparticles for enhanced photothermal therapy, Biomaterials., 143, 29, 10.1016/j.biomaterials.2017.07.027 · DOI
  51. Walker, 2019, Extracellular vesicle-based drug delivery systems for cancer treatment, Theranostics., 9, 8001, 10.7150/thno.37097 · DOI
  52. Moosavian, 2019, Aptamer-functionalized liposomes for targeted cancer therapy, Cancer Lett., 448, 144, 10.1016/j.canlet.2019.01.045 · DOI
  53. Li, 2023, Characterization and Application of Supramolecular Junctions, Angew. Chem. Int. Ed., 62
  54. Zhao, 2020, Chemical vapor deposition and its application in surface modification of nanoparticles, Chem. Pap., 74, 767, 10.1007/s11696-019-00963-y · DOI
  55. Blum, 2001, Nanocomposites by covalent bonding between inorganic nanoparticles and polymers, MRS Proc., 676, 10.1557/PROC-676-Y1.8 · DOI
  56. Zupančič, 2017, Lipophilic peptide character - what oral barriers fear the most, J. Control. Release Off. J. Control. Release Soc., 255, 242, 10.1016/j.jconrel.2017.04.038 · DOI
  57. Shaki, 2018, Self-assembled amphiphilic-dextran nanomicelles for delivery of rapamycin, J. Drug Deliv. Sci. Technol., 44, 333, 10.1016/j.jddst.2018.01.010 · DOI
  58. Nahar, 2006, Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives, Crit. Rev. Ther. Drug Carrier Syst., 23, 259, 10.1615/CritRevTherDrugCarrierSyst.v23.i4.10 · DOI
  59. Purohit, 2022, Polymer Grafting and its chemical reactions, Front. Bioeng. Biotechnol., 10, 1044927, 10.3389/fbioe.2022.1044927 · DOI
  60. Ata, 2018, New developments in non-covalent surface modification, dispersion and electrophoretic deposition of carbon nanotubes, Carbon N. Y., 130, 584, 10.1016/j.carbon.2018.01.066 · DOI
  61. Li, 2019, Peptide-modulated self-assembly as a versatile strategy for tumor supramolecular nanotheranostics, Theranostics., 9, 3249, 10.7150/thno.31814 · DOI
  62. Song, 2019, Supramolecular nanotheranostics based on pillarenes, Theranostics., 9, 3075, 10.7150/thno.31858 · DOI
  63. Yu, 2019, Host-Guest chemistry in supramolecular theranostics, Theranostics., 9, 3041, 10.7150/thno.31653 · DOI
  64. Cheng, 2019, Turn-on supramolecular host-guest nanosystems as theranostics for cancer, Chem., 5, 553, 10.1016/j.chempr.2018.12.024 · DOI
  65. Jin, 2019, Supramolecular nanoscale drug-delivery system with ordered structure, Natl. Sci. Rev., 6, 1128, 10.1093/nsr/nwz018 · DOI
  66. Huang, 2020, Supramolecular self-assembled nanostructures for cancer immunotherapy, Front. Chem., 8, 380, 10.3389/fchem.2020.00380 · DOI
  67. Sercombe, 2015, Advances and challenges of liposome assisted drug delivery, Front. Pharmacol., 6, 10.3389/fphar.2015.00286 · DOI
  68. Kwong, 2013, Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity, Cancer Res., 73, 1547, 10.1158/0008-5472.CAN-12-3343 · DOI
  69. Koshy, 2017, Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy, Adv. Biosyst., 1, 1600013, 10.1002/adbi.201600013 · DOI
  70. Miao, 2017, Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer, ACS Nano, 11, 8690, 10.1021/acsnano.7b01786 · DOI
  71. Chen, 2019, Vasodilator hydralazine promotes nanoparticle penetration in advanced desmoplastic tumors, ACS Nano, 13, 1751
  72. Kulkarni, 2018, A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer, Nat. Biomed. Eng., 2, 589, 10.1038/s41551-018-0254-6 · DOI
  73. Xu, 2022, Visualization of host-guest interactions driven bioorthogonal homing effects at the single cell level in vivo, Nano Today, 43, 10.1016/j.nantod.2022.101450 · DOI
  74. Braegelman, 2019, Integrating stimuli-responsive properties in host-guest supramolecular drug delivery systems, Theranostics., 9, 3017, 10.7150/thno.31913 · DOI
  75. Crini, 2014, Review: a history of cyclodextrins, Chem. Rev., 114, 10940, 10.1021/cr500081p · DOI
  76. Yang, 2022, Suprasomes based on host–guest molecular recognition: an excellent alternative to liposomes in cancer theranostics, Angew. Chem. Int. Ed., 61, 10.1002/anie.202213572 · DOI
  77. Immordino, 2006, Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential, Int. J. Nanomedicine, 1, 297
  78. Yuan, 2019, Hierarchically oriented organization in supramolecular peptide crystals, Nat. Rev. Chem., 3, 567, 10.1038/s41570-019-0129-8 · DOI
  79. Zhang, 2020, Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo, Nat. Nanotechnol., 15, 145, 10.1038/s41565-019-0626-4 · DOI
  80. Li, 2019, Self-assembly: programmable construction of peptide-based materials in living subjects: from modular design and morphological control to theranostics, Adv. Mater., 31, 1970321, 10.1002/adma.201970321 · DOI
  81. Cai, 2020, Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy, Biomater. Sci., 8, 1045, 10.1039/C9BM01380F · DOI
  82. Wen, 2015, Supramolecular peptide vaccines: tuning adaptive immunity, Curr. Opin. Immunol., 35, 73, 10.1016/j.coi.2015.06.007 · DOI
  83. Wu, 2017, A supramolecular vaccine platform based on α-helical peptide nanofibers, ACS Biomater. Sci. Eng., 3, 3128, 10.1021/acsbiomaterials.7b00561 · DOI
  84. Rudra, 2012, Modulating adaptive immune responses to peptide self-assemblies, ACS Nano, 6, 1557, 10.1021/nn204530r · DOI
  85. Hudalla, 2013, A self-adjuvanting supramolecular vaccine carrying a folded protein antigen, Adv. Healthc. Mater., 2, 1114, 10.1002/adhm.201200435 · DOI
  86. Ingale, 2007, Robust immune responses elicited by a fully synthetic three-component vaccine, Nat. Chem. Biol., 3, 663, 10.1038/nchembio.2007.25 · DOI · Paper page
  87. Cai, 2014, Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells, Angew. Chem. Int. Ed., 53, 1699, 10.1002/anie.201308875 · DOI
  88. Cheng, 2018, Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy, Nano Lett., 18, 3250, 10.1021/acs.nanolett.8b01071 · DOI
  89. Han, 2020, Modularly designed peptide nanoprodrug augments antitumor immunity of PD-L1 checkpoint blockade by targeting indoleamine 2,3-dioxygenase, J. Am. Chem. Soc., 142, 2490, 10.1021/jacs.9b12232 · DOI
  90. Ji, 2019, Enhanced natural killer cell immunotherapy by rationally assembling Fc fragments of antibodies onto tumor membranes, Adv. Mater., 31, 1804395, 10.1002/adma.201804395 · DOI
  91. Yang, 2016, Drug delivery via cell membrane fusion using lipopeptide modified liposomes, ACS Cent. Sci., 2, 621, 10.1021/acscentsci.6b00172 · DOI
  92. Pitchaimani, 2018, Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy, Biomaterials., 160, 124, 10.1016/j.biomaterials.2018.01.018 · DOI
  93. Shim, 2010, Efficient and targeted delivery of siRNA in vivo, FEBS J., 277, 4814, 10.1111/j.1742-4658.2010.07904.x · DOI
  94. Nakase, 2015, Combined treatment with a pH-sensitive fusogenic peptide and cationic lipids achieves enhanced cytosolic delivery of exosomes, Sci. Rep., 5, 10112, 10.1038/srep10112 · DOI
  95. Kube, 2017, Fusogenic liposomes as nanocarriers for the delivery of intracellular proteins, Langmuir., 33, 1051, 10.1021/acs.langmuir.6b04304 · DOI
  96. Hayashi, 2019, Endosomal escape by photo-activated fusion of liposomes containing a malachite green derivative: a novel class of photoresponsive liposomes for drug delivery vehicles, Photochem. Photobiol. Sci., 18, 1471, 10.1039/c8pp00495a · DOI
  97. Seeman, 2003, DNA in a material world, Nature., 421, 427, 10.1038/nature01406 · DOI
  98. Zhang, 2019, Holo-lactoferrin modified liposome for relieving tumor hypoxia and enhancing radiochemotherapy of cancer, Small., 15, 1803703, 10.1002/smll.201803703 · DOI
  99. Rothemund, 2006, Folding DNA to create nanoscale shapes and patterns, Nature., 440, 297, 10.1038/nature04586 · DOI
  100. Douglas, 2012, A logic-gated nanorobot for targeted transport of molecular payloads, Science., 335, 831, 10.1126/science.1214081 · DOI
  101. Jiang, 2012, DNA origami as a carrier for circumvention of drug resistance, J. Am. Chem. Soc., 134, 13396, 10.1021/ja304263n · DOI
  102. Zhang, 2019, Interplay of nanoparticle rigidity and its translocation ability through cell membrane, J. Phys. Chem. B, 123, 8923, 10.1021/acs.jpcb.9b07452 · DOI
  103. Chen, 2018, DNA nanotechnology for cancer diagnosis and therapy, Int. J. Mol. Sci., 19
  104. Matsumoto, 2019, Development of DNA-anchored assembly of small extracellular vesicle for efficient antigen delivery to antigen presenting cells, Biomaterials., 225, 10.1016/j.biomaterials.2019.119518 · DOI
  105. Bayón-Cordero, 2019, Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs, Nanomaterials., 9, 10.3390/nano9030474 · DOI
  106. Han, 2011, Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells, J. Biomed. Mater. Res. A, 96, 142, 10.1002/jbm.a.32860 · DOI
  107. Guerrini, 2018, Surface modifications of nanoparticles for stability in biological fluids, Mater. (Basel, Switzerland), 11
  108. Song, 2017, Nanomaterials for cancer immunotherapy, Biomaterials., 148, 16, 10.1016/j.biomaterials.2017.09.017 · DOI
  109. Canavese, 2018, Nanoparticle-assisted ultrasound: a special focus on sonodynamic therapy against cancer, Chem. Eng. J., 340, 155, 10.1016/j.cej.2018.01.060 · DOI
  110. Li, 2018, Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy, Int. J. Nanomedicine, 13, 4107, 10.2147/IJN.S163929 · DOI
  111. Palchetti, 2019, Effect of glucose on liposome-plasma protein interactions: relevance for the physiological response of clinically approved liposomal formulations, Adv. Biosyst., 3, 10.1002/adbi.201800221 · DOI
  112. Nakamura, 2018, Cholesterol blocks spontaneous insertion of membrane proteins into liposomes of phosphatidylcholine, J. Biochem., 163, 313, 10.1093/jb/mvx083 · DOI
  113. Li, 2023, A perspective of engineered lipids and liposomes: chemical design and functional application based on therapeutic safety, Chem. Mater., 35, 4587, 10.1021/acs.chemmater.3c00842 · DOI
  114. Kumar Pramanik, 2017, Physicochemical characterizations of functional hybrid liposomal nanocarriers formed using photo-sensitive lipids, Sci. Rep., 7, 46257, 10.1038/srep46257 · DOI
  115. Nakhaei, 2021, Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol, Front. Bioeng Biotechnol., 9, 10.3389/fbioe.2021.705886 · DOI
  116. Malinge, 2017, Liposomes for PET and MR imaging and for dual targeting (magnetic field/glucose moiety): synthesis, properties, and in vivo studies, Mol. Pharm., 14, 406, 10.1021/acs.molpharmaceut.6b00794 · DOI
  117. Blankenburg, 1989, Interaction between biotin lipids and streptavidin in monolayers: formation of oriented two-dimensional protein domains induced by surface recognition, Biochemistry., 28, 8214, 10.1021/bi00446a037 · DOI
  118. Kleusch, 2012, Fluorescent lipids: functional parts of fusogenic liposomes and tools for cell membrane labeling and visualization, Molecules., 17, 1055, 10.3390/molecules17011055 · DOI
  119. Ji, 2002, Cholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation, J. Biol. Chem., 277, 6273, 10.1074/jbc.M104146200 · DOI
  120. Schade, 2020, Cholesterol review: a metabolically important molecule, Endocr. Pract., 26, 1514, 10.4158/EP-2020-0347 · DOI
  121. Rompicharla, 2017, Formulation optimization, characterization, and evaluation of in vitro cytotoxic potential of curcumin loaded solid lipid nanoparticles for improved anticancer activity, Chem. Phys. Lipids, 208, 10, 10.1016/j.chemphyslip.2017.08.009 · DOI
  122. Park, 2004, Future directions of liposome- and immunoliposome-based cancer therapeutics, Semin. Oncol., 31, 196, 10.1053/j.seminoncol.2004.08.009 · DOI
  123. Sanità, 2020, Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization, Front. Mol. Biosci., 7, 10.3389/fmolb.2020.587012 · DOI
  124. Murugan, 2015, Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures, Int. J. Nanomedicine, 10, 2191
  125. Khalil, 2016, The future of cancer treatment: immunomodulation, CARs and combination immunotherapy, Nat. Rev. Clin. Oncol., 13, 273, 10.1038/nrclinonc.2016.25 · DOI · Paper page
  126. Wei, 2012, Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin, Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci., 46, 131
  127. Wu, 2021, Tip interface exchange-coupling based on “bi-anisotropic” nanocomposites with low rare-earth content, ACS Appl. Mater. Interfaces, 13, 13548, 10.1021/acsami.0c21669 · DOI
  128. Francis, 1998, PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques, Int. J. Hematol., 68, 1, 10.1016/S0925-5710(98)00039-5 · DOI
  129. East, 2011, QD-antibody conjugates via carbodiimide-mediated coupling: a detailed study of the variables involved and a possible new mechanism for the coupling reaction under basic aqueous conditions, Langmuir., 27, 13888, 10.1021/la203273p · DOI
  130. Fontaine, 2015, Long-term stabilization of maleimide–thiol conjugates, Bioconjug. Chem., 26, 145, 10.1021/bc5005262 · DOI
  131. Hein, 2010, Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(I) acetylides, Chem. Soc. Rev., 39, 1302, 10.1039/b904091a · DOI
  132. Katas, 2012, Synthesis of a new potential conjugated TAT-peptide-chitosan nanoparticles carrier via disulphide linkage, J. Nanomater., 2012, 10.1155/2012/134607 · DOI
  133. You, 2018, Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer, Drug Deliv., 25, 448, 10.1080/10717544.2018.1435746 · DOI
  134. Ababneh, 2013, In vitro selection of modified RNA aptamers against CD44 cancer stem cell marker, Nucl. Acid Ther., 23, 401, 10.1089/nat.2013.0423 · DOI
  135. Seydoux, 2016, Pulmonary delivery of cationic gold nanoparticles boost antigen-specific CD4+ T cell proliferation, Nanomedicine, 12, 1815, 10.1016/j.nano.2016.02.020 · DOI
  136. Xiao, 2019, PEGylation and surface functionalization of liposomes containing drug nanocrystals for cell-targeted delivery, Colloids Surf. B: Biointerfaces, 182, 10.1016/j.colsurfb.2019.110362 · DOI
  137. Kono, 2015, Multifunctional liposomes having target specificity, temperature-triggered release, and near-infrared fluorescence imaging for tumor-specific chemotherapy, J. Control. Release Off. J. Control. Release Soc., 216, 69, 10.1016/j.jconrel.2015.08.005 · DOI
  138. Attie, 1995, Analysis of receptor-ligand interactions, J. Chem. Educ., 72, 119, 10.1021/ed072p119 · DOI
  139. Slavoff, 2012, Discovering ligand-receptor interactions, Nat. Biotechnol., 30, 959, 10.1038/nbt.2373 · DOI
  140. Guryanov, 2016, Receptor-ligand interactions: advanced biomedical applications, Mater. Sci. Eng. C, 68, 890, 10.1016/j.msec.2016.07.072 · DOI
  141. Sakurai, 2014, RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system, J. Control. Release Off. J. Control. Release Soc., 173, 110, 10.1016/j.jconrel.2013.10.003 · DOI
  142. Gupta, 2019, Protein PEGylation for cancer therapy: bench to bedside, J. Cell Commun. Signal., 13, 319, 10.1007/s12079-018-0492-0 · DOI
  143. Harris, 2003, Effect of pegylation on pharmaceuticals, Nat. Rev. Drug Discov., 2, 214, 10.1038/nrd1033 · DOI · Paper page
  144. Yadav, 2020, Multifaceted targeting of cationic liposomes via co-delivery of anti-IL-17 siRNA and corticosteroid for topical treatment of psoriasis, Med. Hypotheses, 145, 10.1016/j.mehy.2020.110322 · DOI
  145. Warashina, 2016, A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells, J. Control. Release, 225, 183, 10.1016/j.jconrel.2016.01.042 · DOI
  146. Rawal, 2019, Threatening cancer with nanoparticle aided combination oncotherapy, J. Control. Release Off. J. Control. Release Soc., 301, 76, 10.1016/j.jconrel.2019.03.015 · DOI
  147. Maeda, 2016, A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy—problems, solutions, and prospects, Microcirculation., 23, 173, 10.1111/micc.12228 · DOI
  148. Bae, 2011, Nanomaterials for cancer therapy and imaging, Mol. Cell, 31, 295, 10.1007/s10059-011-0051-5 · DOI
  149. Adiseshaiah, 2010, Nanomaterial standards for efficacy and toxicity assessment, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2, 99, 10.1002/wnan.66 · DOI
  150. Noble, 2009, Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine, Cancer Chemother. Pharmacol., 64, 741, 10.1007/s00280-008-0923-3 · DOI
  151. Ponka, 1999, The transferrin receptor: role in health and disease, Int. J. Biochem. Cell Biol., 31, 1111, 10.1016/S1357-2725(99)00070-9 · DOI
  152. Deshpande, 2013, Current trends in the use of liposomes for tumor targeting, Nanomedicine (London), 8, 1509, 10.2217/nnm.13.118 · DOI
  153. Jiang, 2014, Enhancing the receptor-mediated cell uptake of PLGA nanoparticle for targeted drug delivery by incorporation chitosan onto the particle surface, J. Nanopart. Res., 16, 2453, 10.1007/s11051-014-2453-8 · DOI
  154. Song, 2021, Caveolae-mediated endocytosis drives robust siRNA delivery of polymeric nanoparticles to macrophages, ACS Nano, 15, 8267, 10.1021/acsnano.0c08596 · DOI
  155. Puris, 2022, Targeting transporters for drug delivery to the brain: can we do better?, Pharm. Res., 39, 1415, 10.1007/s11095-022-03241-x · DOI
  156. Pulgar, 2019, Transcytosis to cross the blood brain barrier, new advancements and challenges, Front. Neurosci., 12, 10.3389/fnins.2018.01019 · DOI · Paper page
  157. Guo, 2014, Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering, Biomaterials., 35, 6106, 10.1016/j.biomaterials.2014.04.031 · DOI
  158. Tuma, 2003, Transcytosis: crossing cellular barriers, Physiol. Rev., 83, 871, 10.1152/physrev.00001.2003 · DOI · Paper page
  159. Liang, 2017, Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer, Int. J. Nanomedicine, 12, 1699, 10.2147/IJN.S121262 · DOI
  160. Rommasi, 2021, Liposomal nanomedicine: applications for drug delivery in cancer therapy, Nanoscale Res. Lett., 16, 95, 10.1186/s11671-021-03553-8 · DOI
  161. Borrelli, 2018, Cell penetrating peptides as molecular carriers for anti-cancer agents, Molecules., 23, 10.3390/molecules23020295 · DOI
  162. Ding, 2015, An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery, Int. J. Nanomedicine, 10, 6199
  163. Derakhshankhah, 2018, Cell penetrating peptides: a concise review with emphasis on biomedical applications, Biomed. Pharmacother., 108, 1090, 10.1016/j.biopha.2018.09.097 · DOI
  164. Ruseska, 2020, Internalization mechanisms of cell-penetrating peptides, Beilstein J. Nanotechnol., 11, 101, 10.3762/bjnano.11.10 · DOI
  165. Chen, 2017, Peptide-22 and cyclic RGD functionalized liposomes for glioma targeting drug delivery overcoming BBB and BBTB, ACS Appl. Mater. Interfaces, 9, 5864, 10.1021/acsami.6b15831 · DOI
  166. Kibria, 2011, Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery, J. Control. Release Off. J. Control. Release Soc., 153, 141, 10.1016/j.jconrel.2011.03.012 · DOI
  167. Schiffelers, 2003, Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin, J. Control. Release Off. J. Control. Release Soc., 91, 115, 10.1016/S0168-3659(03)00240-2 · DOI
  168. Saber, 2017, Targeted drug delivery of Sunitinib Malate to tumor blood vessels by cRGD-chiotosan-gold nanoparticles, Int. J. Pharm., 517, 269, 10.1016/j.ijpharm.2016.12.016 · DOI
  169. Ahmad, 2021, Targeting integrins for cancer management using nanotherapeutic approaches: recent advances and challenges, Semin. Cancer Biol., 69, 325, 10.1016/j.semcancer.2019.08.030 · DOI
  170. Cheng, 2008, Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab’ fragments and single chain Fv, J. Control. Release Off. J. Control. Release Soc., 126, 50, 10.1016/j.jconrel.2007.11.005 · DOI
  171. Collins, 2022, Soluble papain to digest monoclonal antibodies; time and cost-effective method to obtain fab fragment, Bioengineering., 9, 10.3390/bioengineering9050209 · DOI
  172. Ohradanova-Repic, 2018, Fab antibody fragment-functionalized liposomes for specific targeting of antigen-positive cells, Nanomedicine., 14, 123, 10.1016/j.nano.2017.09.003 · DOI
  173. Nelson, 2010, Antibody fragments: hope and hype, MAbs., 2, 77, 10.4161/mabs.2.1.10786 · DOI
  174. Wang, 2020, Aptamer-functionalized polydiacetylene liposomes act as a fluorescent sensor for sensitive detection of MUC1 and targeted imaging of cancer cells, Sensors Actuators B Chem., 309, 10.1016/j.snb.2020.127778 · DOI
  175. Mann, 2011, Thioaptamer conjugated liposomes for tumor vasculature targeting, Oncotarget., 2, 298, 10.18632/oncotarget.261 · DOI
  176. Chowdhury, 2020, Targeted delivery of doxorubicin liposomes for her-2+ breast cancer treatment, AAPS PharmSciTech, 21, 202, 10.1208/s12249-020-01743-8 · DOI
  177. Alshaer, 2018, Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model, J. Control. Release Off. J. Control. Release Soc., 271, 98, 10.1016/j.jconrel.2017.12.022 · DOI
  178. Aires Fernandes, 2021, Transferrin-functionalized liposomes for docetaxel delivery to prostate cancer cells, Coll. Surf A Physicochem. Eng. Asp., 611, 10.1016/j.colsurfa.2020.125806 · DOI
  179. Deshpande, 2018, Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer, Drug Deliv., 25, 517, 10.1080/10717544.2018.1435747 · DOI
  180. Du Nguyen, 2019, Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo, Colloids Surf. B: Biointerfaces, 173, 539, 10.1016/j.colsurfb.2018.10.013 · DOI
  181. Prabaharan, 2009, Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery, Biomaterials., 30, 6065, 10.1016/j.biomaterials.2009.07.048 · DOI
  182. Wang, 2019, Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of shikonin/JQ1, Nano Lett., 19, 2935, 10.1021/acs.nanolett.9b00021 · DOI
  183. Wei, 2015, Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma, Int. J. Nanomedicine, 10, 5123
  184. Pireddu, 2018, A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine, Int. J. Pharm., 537, 257, 10.1016/j.ijpharm.2017.12.048 · DOI
  185. Bulbake, 2017, Liposomal formulations in clinical use: an updated review, Pharmaceutics., 9, 10.3390/pharmaceutics9020012 · DOI
  186. Riaz, 2018, Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review, Int. J. Mol. Sci., 19, 10.3390/ijms19010195 · DOI
  187. Fan, 2019, Functionalized DNA enables programming exosomes/vesicles for tumor imaging and therapy, Small., 15, 1903761, 10.1002/smll.201903761 · DOI
  188. Apte, 2014, Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models, Cancer Biol. Ther., 15, 69, 10.4161/cbt.26609 · DOI
  189. Lin, 2020, Application of paclitaxel-loaded EGFR peptide-conjugated magnetic polymeric liposomes for liver cancer therapy, Curr. Med. Sci., 40, 145, 10.1007/s11596-020-2158-4 · DOI
  190. Lopes, 2022, Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin, Drug Deliv Transl. Res., 12, 629, 10.1007/s13346-021-00972-z · DOI · Paper page
  191. Zhang, 2018, Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine-docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo, Drug Deliv., 25, 723, 10.1080/10717544.2018.1446475 · DOI
  192. Ding, 2017, In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors, Drug Des. Devel. Ther., 11, 3105, 10.2147/DDDT.S149814 · DOI
  193. Fu, 2015, Tumor-targeted paclitaxel delivery and enhanced penetration using TAT-decorated liposomes comprising redox-responsive poly(ethylene glycol), J. Pharm. Sci., 104, 1160, 10.1002/jps.24291 · DOI
  194. Feng, 2019, Engineering of bone- and CD44-dual-targeting redox-sensitive liposomes for the treatment of orthotopic osteosarcoma, ACS Appl. Mater. Interfaces, 11, 7357, 10.1021/acsami.8b18820 · DOI
  195. Wang, 2020, A Novel CD133- and EpCAM-targeted liposome with redox-responsive properties capable of synergistically eliminating liver cancer stem cells, Front. Chem., 8, 649, 10.3389/fchem.2020.00649 · DOI
  196. Kwong, 2011, Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy, Biomaterials., 32, 5134, 10.1016/j.biomaterials.2011.03.067 · DOI
  197. Chiu, 2007, Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs, Mol. Cancer Ther., 6, 844, 10.1158/1535-7163.MCT-06-0159 · DOI
  198. Zheng, 2013, In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes, J. Control. Release Off. J. Control. Release Soc., 172, 426, 10.1016/j.jconrel.2013.05.037 · DOI
  199. Fan, 2017, Immunogenic cell death amplified by Co-localized adjuvant delivery for cancer immunotherapy, Nano Lett., 17, 7387, 10.1021/acs.nanolett.7b03218 · DOI
  200. Lu, 2016, Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach, Cancer Lett., 379, 32, 10.1016/j.canlet.2016.05.025 · DOI

200 of 420 shown

Cited by

Sorted by citations

Metadata

Authors
Tiwari, P., Yadav, K., Shukla, R. P., Gautam, S., Marwaha, D., Sharma, M., & Mishra, P. R.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2023-11
Volume
363
Pages
290-348
ISSN
0168-3659
DOI
10.1016/j.jconrel.2023.09.016
Cited by
88
References
18
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review